Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteomic biomarker evaluation of eplerenone versus spironolactone after myocardial infarction
2008-001192-29Phase 4Active
- Sponsor
- Fundación Interhospitalaria para la Investigación Cardiovascular
- Start
- May 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of eplerenone and spironolactone in myocardial infarction (MI), hypertension (HTN), type 2 diabetes mellitus (T2DM) and 1 more (2 arms), sponsored by Fundación Interhospitalaria para la Investigación Cardiovascular. Primary endpoints: Proteomic expression of plasma protein biomarkers, Proteomic biomarkers of vascular and myocardial injury and 1 more. Started May 2008; status: active.
02
Drugs
eplerenonespironolactone
03
Conditions
myocardial infarction (MI)hypertension (HTN)type 2 diabetes mellitus (T2DM)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2008-001192-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001192-29.